Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LGMN | Q99538 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259671 | 0.90 | NPC1 (0.82) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL31114781 | 0.90 | NPC1 (0.82) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL12200473 | 0.82 | SMN1; SMN2 (0.70) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL10347934 | 0.82 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL75492 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL3711629 | 0.81 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL10271550 | 0.80 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL10348026 | 0.80 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL10219999 | 0.79 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL28617302 | 0.79 | PIK3CA (1.00) | RAB9ANPC1SMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585599-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| CN-120136812-A | Compound for targeted degradation of transcription factor KLF5 and application thereof | 昆明医科大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-4545525-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | Parenchyma Biotech Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-12187717-B2 | Compound and use thereof in treating autoimmune diseases | PARENCHYMA BIOTECH INC. (KR) | 2025-01-07 | — | — | US | disclosed |
| CN-119233975-A | Novel compounds and their use for the treatment of autoimmune diseases | 帕连齐玛生物技术株式会社 | 2024-12-31 | — | — | CN | disclosed |
| CN-117946138-A | And ring nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023249228-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | 파렌키마바이오텍 주식회사 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249228-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | 파렌키마바이오텍 주식회사 | 2023-12-28 | — | — | WO | disclosed |
| US-20230406848-A1 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | PARENCHYMA BIOTECH INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| CN-115109011-B | Benzothiazole compound, preparation method and application | 河北师范大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-0122831-B1 | BENZOTHIAZOLE-2-SULFONAMIDE DERIVATIVES FOR THE TOPICAL TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-04-18 | — | — | EP | disclosed |
| US-4499103-A | Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0122831-A2 | Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406848-A1 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | GSTA1, BRCA1, BACH1 | RAB9A 1392/4885NPC1 1483/4885SMN1; SMN2 1593/4885 |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | RAB9A 2687/4885NPC1 1112/4885SMN1; SMN2 1354/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | RAB9A 3357/4885NPC1 1204/4885SMN1; SMN2 1288/4885 |
| US-12187717-B2 | Compound and use thereof in treating autoimmune diseases | GSTA1, BRCA1, BACH1 | RAB9A 1392/4885NPC1 1483/4885SMN1; SMN2 1593/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | RAB9A 3007/4885NPC1 3817/4885SMN1; SMN2 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.